Portrait of PTEN: Messages from mutant mice

Cancer Science

Volumn 99, Issue 2, 2008, Pages 209-213

  Suzuki, Akira ^a,b   Nakano, Toru ^b   Mak, Tak Wah ^c   Sasaki, Takehiko ^d  

^a KYUSHU UNIVERSITY   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Graduate School of Frontier Biosciences   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ACYL COENZYME A OXIDASE; ANDROGEN RECEPTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CONNEXIN 40; EPHRIN B2; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FOCAL ADHESION KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN SHC; RAD51 PROTEIN; RAS PROTEIN; SOS PROTEIN; TRANSCRIPTION FACTOR FKHR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

BREAST TUMOR; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; COWDEN SYNDROME; ENDOMETRIUM CANCER; ENZYME ACTIVATION; GENE DELETION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOLOGICAL TOLERANCE; KERATINOCYTE; LIVER CELL; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MOUSE MUTANT; NATURAL KILLER T CELL; NONHUMAN; PARANEOPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEBACEOUS CARCINOMA; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; THYROID TUMOR; TRANSITIONAL CELL CARCINOMA;

ANIMALS; AUTOIMMUNE DISEASES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; KERATINOCYTES; LUNG; MICE; MICE, MUTANT STRAINS; MUTATION; PHENOTYPE; PTEN PHOSPHOHYDROLASE; T-LYMPHOCYTES; UROTHELIUM;

EID: 39049101676     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00670.x     Document Type: Review

References (72)

1. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387: 673-6.
2. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
3. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-90.
4. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13.375-8.
5. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-17.
6. Gu J, Tamura M, Pankov R et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999; 146: 389-403.
7. Mahimainathan L, Choudhury GG. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 2004; 279: 15.258-68.
8. Liu Q, Sasaki T, Kozieradzki I et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 1999; 13: 786-91.
9. Fukui K, Wada T, Kagawa S et al. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5′-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 2005; 54: 1958-67.
10. Stokoe D. Pten. Curr Biol 2001; 11: R502.
11. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-7.
12. Suzuki A, de la Pompa JL, Stambolic V et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-78.
13. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/ Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
14. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-55.
15. Podsypanina K, Ellenson LH, Nemes A et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-8.
16. +/-mice. Science 1999; 285: 2122-5.
17. Suzuki A, Yamaguchi MT, Ohteki T et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523-34.
18. Sasaki T, Irie-Sasaki J, Jones RG et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-6.
19. Borlado LR, Redondo C, Alvarez B et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14: 895-903.
20. Suzuki A, Itami S, Ohishi M et al. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 2003; 63: 674-81.
21. Zhao M, Song B, Pu J et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature 2006; 442: 457-60.
22. Horie Y, Suzuki A, Kataoka E et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-83.
23. Tsuruta H, Kishimoto H, Sasaki T et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006; 66: 8389-96.
24. Logie A, Dunois-Larde C, Rosty C et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005; 14: 1153-60.
25. Cheng J, Huang H, Zhang ZT et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002; 62: 4157-63.
26. Zhang ZT, Pak J, Huang HY et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 1973-80.
27. Yanagi S, Kishimoto H, Kawahara K et al. Pten controls lung morphogenesis, bronchoalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest 2007; 117: 2929-40.
28. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10.931-4.
29. Cui J, Shin T, Kawano T et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623-6.
30. Hamada K, Sasaki T, Koni PA et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19: 2054-65.
31. Kishimoto H, Ohteki T, Yajima N et al. The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells. Blood 2007; 109: 3316-24.
32. Kimura T, Suzuki A, Fujita Y et al. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 2003; 130: 1691-700.
33. Backman SA, Ghazarian D, So K et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA 2004; 101: 1725-30.
34. Wang S, Gao J, Lei Q et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-21.
35. Stanger BZ, Stiles B, Lauwers GY et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005; 8: 185-95.
36. Li G, Robinson GW, Lesche R et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-70.
37. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: Insights into thyroid function and Cowden disease pathogenesis. Cancer Res 2007; 67: 959-66.
38. Xu X, Kobayashi S, Qiao W et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006; 116: 1843-52.
39. Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13: 748-53.
40. Kwabi-Addo B, Giri D, Schmidt K et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001; 98: 11.563-8.
41. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 2006; 103: 1480-5.
42. He XC, Yin T, Grindley JC et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007; 39: 189-98.
43. Groszer M, Erickson R, Scripture-Adams DD et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001; 294: 2186-9.
44. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-70.
45. Crackower MA, Oudit GY, Kozieradzki I et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110: 737-49.
46. Wijesekara N, Konrad D, Eweida M et al. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol Cell Biol 2005; 25: 1135-45.
47. Backman SA, Stambolic V, Suzuki A et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001; 29: 396-403.
48. Suzuki A, Kaisho T, Ohishi M et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197: 657-67.
49. Liu X, Bruxvoort KJ, Zylstra CR et al. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 2007; 104: 2259-64.
50. Malstrom S, Tili E, Kappes D, Ceci JD, Tsichlis PN. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci USA 2001; 98: 14.967-72.
51. +/-mice. Genes Dev 2006; 20: 1569-74.
52. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379-86.
53. Sibilia M, Fleischmann A, Behrens A et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2000; 102: 211-20.
54. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999; 274: 22033-40.
55. Gil A, Andres-Pons A, Pulido R. Nuclear PTEN: A tale of many tails. Cell Death Differ 2007; 14: 395-9.
56. Baker SJ. PTEN enters the nuclear age. Cell 2007; 128: 25-8.
57. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 2005; 65: 8096-100.
58. Chung JH, Ginn-Pease ME, Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005; 65: 4108-16.
59. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005; 25: 6211-24.
60. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002; 99: 63-7.
61. Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3: 117-30.
62. Chen Z, Trotman LC, Shaffer D et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-30.
63. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. Embo J 2004; 23: 212-20.
64. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA 2005; 102: 2703-6.
65. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 2006; 103: 14.477-82.
66. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25: 329-37.
67. Fan W, Yanase T, Morinaga H et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007; 282: 7329-38.
68. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 2004; 18: 2409-23.
69. Gao H, Ouyang X, Banach-Petrosky WA, Shen MM, Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in nkx3.1; pten mice. Cancer Res 2006; 66: 7929-33.
70. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-24.
71. +/-mice. Cancer Res 2006; 66: 3375-80.
72. Lee JO, Yang H, Georgescu MM et al. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99: 323-34.